In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at ...
A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...
Biohaven Ltd. (NYSE:BHVN) is one of the 10 Small–Cap Stocks Insiders Are Buying Recently. On March 19, 2026, Biohaven Ltd.
Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates ...
In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results